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Abstract 
The sensory contact model allows forming different psychopathological states (anxious depression, 
catalepsy, social withdrawal, pathological aggression, cognition disturbances, anhedonia, addictive 
states etc.) produced by repeated agonistic interactions in male mice and investigating the therapeutic 
and preventive properties of any drug as well as its efficiency under simulated clinical conditions. This 
approach can be useful for a better understanding of the drugs’ action in different stages of disease 
development in individuals. It is suggested that this behavioral approach and pharmacological designs 
may be applied for the screening of novel psychotropic drugs*.  
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* Full text of this MS and list of  all references are presented on arXiv:0707.3671 [q-bio.OT] 
http://arxiv.org/ftp/arxiv/papers/0707/0707.3671.pdf   
Introduction 
Pharmacological approach is based on the model 
of chronic social conflicts or the so-called “sensory 
contact model” [1-4], which was originally used for 
study the mechanisms of aggressive and submissive 
behaviors of male mice (beginning at 1987-1991 
years). Pairs of male mice are placed in cages 
divided in two compartments by a perforated 
transparent partition allowing the animals to see, 
hear and smell their neighbor, but not to contact 
them physically. Every day the partition was 
removed for 10 min to allow agonistic interactions. 
Superiority of one of the partners was evident within 
3 daily test sessions with the same partner. One 
partner attacked, bitted, and chased the other, who 
displayed defensive behavior only (sideways, 
upright postures, withdrawal, lying on the back or 
freezing). Agonistic interactions were discontinued 
by lowering the partition if intensive attacks lasted 
more than 3 min. Every day after the test session, 
each defeated mouse was placed in another two 
compartments cage with a partition, in which 
another winner was present in the other 
compartment. The winners remained in their own 
compartments. The sensory contact model yielded 
equal numbers of males with experience of 
aggression, evidenced by victories (aggressors, 
winners) and with social defeats (defeated mice, 
losers) in agonistic interactions. Winners and losers 
after 2-3, 10 and 20 tests of daily agonistic 
interactions were used in the experiments. Control 
males were housed  individually  for  5  days.  They  
 
were regarded as the most appropriate controls 
for the sensory contact model, because the 
submissiveness of grouped males was removed, 
and the effects of social isolation were not yet 
acquired [1, 2]. 
It was shown that repeated experience of 
social victories or defeats in daily agonistic 
interactions leads to the formation of persistent 
opposing kinds of social behavior in male mice – 
the winners (aggressors) and losers (defeated 
animals, victims of aggression). Depending on 
emotional state (positive or negative) of an 
individual, multiple neurochemical alterations in 
the synthesis, catabolism and receptors of key 
brain neurotransmitters are followed by 
behavioral and physiological changes in mice. In 
general, it was shown that repeated experience of 
aggression is accompanied by the activation of 
brain dopaminergic and opioidergic systems and 
hypofunction of serotonergic system [reviews, 2, 
3] while repeated experience of social defeats 
leads to the attenuation of the dopaminergic and 
serotonergic brain activity [review, 2, 4]. As a 
consequence, the winners and losers were found 
to exhibit significant differences in emotionality, 
motor and exploratory activities, level of 
sociability, alcohol intake as well as in the state 
of immune system and gonadal function [2]. It 
was also shown that long exposure to social 
confrontations   leads   to   the   formation   of 
psychoemotional and somatic disturbances with  
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the forming behavioral pathology depending on 
kind of social behaviors, duration of agonistic 
interactions and strain of mice (Table). In our 
studies, eight criteria used were thought to point to 
the formation of behavioral pathology (Box) [3]. 
The most extensive studies have been conducted and 
the most satisfactory validating results obtained on 
mice for anxious depression, generalized anxiety, 
pathological aggression and psychogenic immune 
deficiency [3-7]. Generating different psychoemo-
tional and psychosomatic disturbances in animals 
under the sensory contact model gives the 
opportunity to investigate the action of novel (along 
with widely used) psychotropic drugs and conduct  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
their screening in the simulated clinical 
conditions. In this respect, it would be useful to 
outline possible applications of the proposed 
experimental method and new pharmacological 
designs for detecting therapeutic and protective 
effects and efficacy of prospective psychotropic 
drugs. 
 
The study of therapeutic (medicative) effect of 
drugs with prospective psychotropic 
properties 
The general design of the experiments is as 
follows (Fig. 1a): during 20-30 days a 
psychoemotional disorder   is  induced   in  male  
 
 
 
 
 
 
 
 
SUBMISSIVE  MICE AGGRESSIVE MICE 
Behavioral Pathologies and 
Psychosomatic Disorders Strain Refs* Behavioral Pathologies Strain Refs* 
Generalized anxiety  
Anxious depression  
Depression 
С57 [4, 5, 9] Pronounced anxiety   
CBA 
C57 [3] 
Low communication  
Social withdrawal (autism?) 
С57 
СВА 
[4, 5, 9, 
26] 
High impulsivity 
Pathological aggression  C57 [3] 
Behavioral deficit  С57 [4, 5, 9] Hyperactivity CBA [3] 
Increased ethanol intake   
Anhedonia С57 [30, 31] Addiction to aggression C57 [3] 
Catalepsy СВА [32] Stereotypic behavior CBA [3, 32] 
Decreased pain sensitivity С57 [4] Hypersensitivity,  Enhanced irritability 
С57 
CBA [3] 
Cognition dysfunction С57 [33] Cognition dysfunction C57 [3, 37] 
Sexual dysfunction  
Decreased fertility  С57 [34, 35] Sexual dysfunction  C57 [3, 34] 
Immune deficiency  
Increased metastasis  
СВА 
С57 
[6, 7, 
36] Learned aggression 
CBA 
C57 [3] 
Box:     Criteria used to determine the development of behavioral pathology in male mice under 
repeated experience of social confrontations [3]: 
 Change (increase or decrease) in the duration and/or expression of demonstration of behavioral forms;  
 Emergence of novel behavioral forms, which have not been demonstrated by animals before; 
 Inadequacy of behavioral response or physiological reaction to some social or environmental stimuli; 
uncontrollable behavior in some circumstances;  
 Inadaptability of behavior in given environmenttal conditions or experimental situations;  
 Generalization of dominating motivation; 
 Prolonged retention (persistence) of changes in behavior and psychoemotional state after the cessation 
of psychopathogenic factor action; 
 Expressed multiple neurochemical alterations in the brain; 
 Similarity of behavioral pathology occurring in mice to clinical picture of a human disease: similarity 
of etiology, symptomatology, sensitivity to the drugs used for the treatment of such a disease and also 
the similarity of neurochemical alterations arising in mice and humans as the disease progresses. This 
criterion originally suggested for models of depression [38] may be extended for all experimental 
psychopathologies.
Table.  Different psychoemotional and somatic pathologies developing in aggressive and 
submissive male mice of C57BL/6J (C57) and CBA/Lac (CBA) strains after long 
experience of agonistic interactions under the sensory contact model
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mice by repeated social agonistic interactions, which 
are inevitably followed by psychosomatic changes. 
Then the “sick” animals are put into comfortable 
housing conditions (without daily agonistic 
interactions) to start chronic (1-2 times a day for at 
least 2 weeks) administration of the drug under 
investigation. At the same time, other group of 
“sick” animals is treated with placebo (vehicle) in 
analogous conditions (Fig. 1a). Upon the completion 
of “treatment” the two groups of animals are 
compared (using relevant behavioral or 
physiological tests) to detect therapeutic effect of 
the drug. By comparing “sick” placebo-treated 
animals, with drug-treated “sick” animals it is 
possible to detect positive or negative effect of the 
drug. Behavior of intact healthy animals (control, 
norm), which have not been exposed to any 
treatment, is also studied. By comparing the control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
with “sick” individuals, who have been treated 
with the drug, the efficiency of the drug action 
could be determined, i.e. to what extent the drug 
has improved the behavioral or physiological 
characteristics as compared with those in the 
control. Anxiolytic effects of lithium-based 
enterosorbent Noolit (Fig. 1b,c) [5] and 
antidepressive effect of fluoxetine (Fig. 1d) 
[Kovalenko et al., unpublished data] used in 
clinics [8] were shown in depressive mice after 
medicative (therapeutic) treatment. It was 
assumed that this regimen of treatment imitates 
the conditions of clinical treatment of patients. It 
should be noted that in the experiments positive 
action of the drugs was manifested after two 
weeks of treatment. However to verify a 
sustained effect of drugs they are to be adminis-
tered for a longer time,  possibly,  two  months, 
(a)           C o m f o r t a b l e   c o n d i t i o n sA g o n i s t i c   i n t e r a c t i o n s
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 days
Development of behavioral pathology       Drug treatment
 
         
      
Open field test Porsolt's test(c) (d)Plus-maze test(b)
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%
**
**
#
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0
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#
Controls Vehicle Noolit
N
"Depressive" mice
Passive swimming
0
40
80
120
160
200
s
*
*
##
Controls Vehicle Fluoxetine
"Depressive" mice
Fig. 1. Regimen of medicative treatment. A psychoemotional disorder (for example, depression state) is induced in male 
mice by repeated social agonistic interactions during 20 days (a). Then the depressive animals are put into comfortable 
housing conditions without confrontations and are treated during 2 weeks with drug or placebo (vehicle). Upon treatment 
the three groups of animals - placebo-treated and drug-treated depressive mice as well as the control are compared (using 
relevant behavioral tests) to detect therapeutic effect of the drug. Behavior of depressive mice in the plus-maze test, open-
field test and Porsolt’s tests after medicative chronic treatment by lithium-based enterosorbent noolit (665 mg/kg) (b,c) [5] 
and fluoxetine (25 mg/kg) (d) were shown. Depressive animals (vehicle-treated) have high level of anxiety (increased % 
entries to enclosed arms) in elevated plus-maze test (b), reduced exploratory activity (decreased number of rearing) in the 
open field test (c) and high level of depressiveness (total time of passive swimming) in Porsolt’s test (d) as compared with 
the control (intact state). Noolit reduced level of anxiety and increased exploratory activity as compared with placebo-
treated mice. Number of rearings (c) under noolit treatment restored to the level in the control. Enclosed arm time (b) and 
time of passive swimming (d) were decreased in drug-treated animals as compared with vehicle-treated animals but differ 
from intact animals.  * p < 0.05, ** p < 0.01 vs controls; # p < 0.05; ## p < 0.01, vs vehicle-treated depressive mice.
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similarly to the clinical treatment of depression in 
humans. Besides, additional studies of animals after 
treatment are needed to predict the probability and 
incidence of relapses, which are quite common in 
patients with psychoemotional disorders. 
 
Detection of protective properties of drugs 
     As a rule, an individual is incapable of avoiding 
or at least minimizing negative influence of social 
environment and surroundings, in which he or she 
lives or has to stay in particular living 
circumstances. In such cases the questions arise on 
how to prevent the development of a disease under 
long exposure to psychopathogenic factors? Our 
approach allows detecting protective effects of 
drugs administered for preventive purposes under 
exposure to chronic agonistic interactions. For that, 
after five days of social interactions, animals are 
treated chronically by drugs on the background of 
continuing daily agonistic interactions (Fig. 2a). At 
the same time, in analogous way a group of animals 
receives a placebo (vehicle). After a period of time, 
which is to be not shorter than two weeks for drugs 
with assumed psychotropic properties, all animals 
are investigated in relevant behavioral or 
physiological tests. This regimen was used to admi- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
nister the drugs that are used in the clinical 
practice for reduction of depression and anxiety 
and that influence the serotonergic system, which 
undergoes alterations in the process of 
depression formation in male mice [4, 9].  It has 
been shown (as example, see Fig. 2b,c,d) that 
buspirone, insapirone and tianeptine (but not 
fluoxetine and citalopram) produced anxiolytic 
effect, i.e. the level of developing anxiety on the 
background of chronic preventive drug 
administration was lower at least in one of the 
behavioral test as compared with placebo-treated 
animals, which points to protective effect of 
these drugs. Imipramine and tianeptine were 
shown to prevent the development of high level 
of depressiveness while buspirone appears to 
have a lower antidepressive potency [4, 9]. 
Naturally, a question arises: what underlies 
different efficacy of medications? It could 
depend on the dosage, regimen and duration of 
treatment. It should not be also excluded that 
under exposure to persisting powerful stress a 
complex psychotropic medication rather than 
mono-therapy with a single drug is needed. 
Nevertheless, twenty years of work with the 
model have given us the understanding that 
different stages of the disease may require 
different treatments depending on the state of the  
                (a)                        
Drug treatment
A g o n i s t i c   i n t e r a c t i o n s
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 days 
 
    
               
Porsolt's test(c) (d)Plus-maze testPlus-maze test(b)
 
Open arm time
*
0
1
2
3
4
%
Vehicle  Buspirone
Open arm time
*
0.0
0.5
1.0
1.5
2.0
2.5
%
Vehicle   Ipsapirone
Immobility
*
0
50
100
150
Vehicle  Tianeptine
s
Fig. 2. Regimen of preventive treatment. After five days of social interactions forming opposite social behaviors, 
animals are treated chronically by drugs with assumed or known therapeutic properties. At the same time, in analogous 
way a group of animals receives a placebo. Agonistic interactions are continuing all period of treatment (a). After two 
weeks all animals are investigated in relevant behavioral tests. This regimen was used to administer the drugs that are used 
in the clinical practice for reduction of depression and/or anxiety. 5-HT1A receptors agonists buspirone (1 mg/kg) (b) and 
ipsapirone (3 mg/kg) (c) decreased high level of anxiety developing in defeated mice during agonistic interactions and 
increased % open arm time in elevated plus-maze test. Antidepressant tianeptine (10 mg/kg) (d) prevented development of 
high level of deperessivenes estimated by Porsolt’ test (decrease of immobility time) [4].  * p < 0.05 as compared with 
defeated male mice receiving vehicle (placebo). 
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brain neurotransmitter systems involved in the 
pathological process.  
 
Study of the drug effects depending on the stage 
of psychoemotional disorder 
Neurochemical studies have produced a bulk of 
evidence that under repeated experience of 
aggression or social defeats the brain 
neurotransmitter systems undergo specific dynamic 
changes in synthesis, catabolism and receptors [3, 
4]. The consequences of chronic confrontations 
seem to be accumulated and the occurring 
neurochemical changes may differ depending on the 
duration of psychoemotional stress and the depth of 
developing behavioral pathology. An obvious 
implication of all the experiments is that 
psychoemotional disorders like many other ailments 
do not emerge out of the blue (all at once), this is 
rather a process in time,  when  the  accumulating 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
changes aggravate the state. Direct evidence was 
obtained in the study of the mouse brain 
serotonergic system during the formation of 
anxious depression, revealing dynamic 
alterations of serotonin synthesis, catabolism and 
receptors [4, 9]. On the base of these studies it 
was concluded that during the first days of 
confrontations social stress evokes the activation 
of the brain serotonergic system in animals. 
Subsequently, under systematic psychoemotional 
negative impact a hypofunction of the 
serotonergic system is formed at least in limbic 
brain areas of depressive mice.  
     In our studies we develop pharmacological 
approach, which allows estimating possible 
changes in brain neurochemical activity during 
the formation of psychoemotional disorders (Fig. 
3a). For this purpose, preliminarily chosen dose 
of a drug is administered into intact animals and 
animals in different stages of “disease” – after 
      (a)                  
A g o n i s t i c   i n t e r a c t i o n s
Control
Acute
stress
Developing
pathology
Deep
pathology
Intact
mice
1  2  3  4   5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20 21 days
 
     
Plus-maze testAgonistic interactions(c) (d)Plus-maze test(b)
 
           
Open arm time
#
**
0
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15
20
Controls T20
%Hostile behavior
*
*
0
50
100
150
200
250
300
T3 T20
sOpen arm time
**
*
0
5
10
15
20
T3 T20
%
 
vehicle diazepam 8-OH-DPATvehicle
Fig. 3. Study of the drug effects depending on the stage of psychoemotional disorder. The same dose of a drug and placebo 
(vehicle) is administered into intact animals and animals in different stages of “disease” – after 2-3 days of social 
confrontations - initial stage (acute social stress), 10 days – developing pathology and 20 days – deep pathology (a). 
Comparison of the drug effect is conducted in the every experimental group by comparing the tested behavior of drug-treated 
animals with that of the vehicle-treated one. Fig. 3 (b,c) demonstrates effect of single diazepam injection (0.5 mg/kg) in the 
winners after 3 (Т3) and 20 (Т20) agonistic interactions on the behavior in the elevated plus-maze test (b) and on the hostile 
behavior (attacks, threats etc) toward the partner during agonistic interactions (c) [39]. Diazepam produced anxiogenic effect 
(decrease of % open arm time) in males with a short experience of aggression (Т3), anxiolytic effect (increase of % open arm 
time) in males with a long experience of aggression (Т20) and reduced the total time of hostile behavior in both groups of 
aggressive males [39]. 5-HT1A receptor agonist 8-OH-DPAT (0.5 mg/kg) produced anxiogenic effect (decrease of open arm 
time (%) in the elevated plus-maze test) in the controls and was ineffective in depressive males after 20 days confrontations 
(T20) [D. Avgustinovich et al., unpublished]. * p < 0.05; ** p<0.001 vs vehicle. # p < 0,001 vs vehicle-treated controls. 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
07
.1
43
9.
1 
: P
os
te
d 
19
 D
ec
 2
00
7
6 
 
0
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120
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0   0.6 1.25  2.5 0   0.6  1.25  2.5 0   0.6  1.25  2.5 
Total time, s
Losers
**
#
* **
*
 
Fig. 4. Effect of selective k-opioid receptor agonist U-
50,488Н (0.6, 1.25 and 2.5 mg/kg) on communicative 
behavior of the control, the winners and losers after 10 days 
of agonistic interactions. Level of communicative behavior 
was estimated in the partition test, measuring behavioral 
reaction to the partner in the neighboring compartment of  
common cage. It was shown that U-50,488H produced decrease 
of total time spent near the partition (social withdrawal) in the 
control animals, had no effect on the winners and increased this 
behavior in the losers (anxiolytic effect) [40]. * p < 0.05; ** p < 
0.01 – as compared with vehicle (0); # p < 0.05 – as compared 
with previous dose of the drug. 
 
2-3 days of confrontations – initial stage (acute 
social stress), 10 days – developing pathology and 
20 days of confrontations – deep pathology. 
Comparison of the drug effect is conducted in the 
every experimental group by comparing the tested 
behavior of drug-treated animals with that of the 
vehicle-treated. Diverse effects of the drug as 
regards the intensity or direction in intact and “sick” 
mice point to a changed state of a mediator system 
involved in the pathogenic process. With the help of 
this method it was shown that different stages of 
disease are often characterized by dissimilar reaction 
to many drugs. We have obtained experimental 
evidence supporting these views for many drugs 
used in clinics: haloperidol, naltrexone, buspirone, 
diazepam etc (as example, see Fig. 3) [3, 4].  
Therefore, it is obvious that different stages of a 
disease require different drug correction depending 
on the status of brain neurotransmitter activity. In 
this respect the sensory contact model, which allows 
monitoring the changes in neurochemical activity of 
the brain as a disease progresses from norm to deep 
pathology, could be used for screening psychotropic 
drugs to determine their efficacy in different stages 
of the pathological process.  
 
The study of the individual sensitivity to drug 
depending on psychoemothional states 
It is well known that the many of modern drugs are 
effective in less than half of all psychiatric patients. 
This is thought to be due to individual peculiarities 
of diseased organisms having varying hereditary 
sensitivity to drugs. The role of hereditary factor 
can be elucidated in the experiments with 
animals of inbred strains reacting differently to 
the drugs administered. However, our experi-
ments demonstrated that one and the same 
behavioral or physiological parameter under the 
influence of a drug could change in different 
ways in animals of one inbred strain but with the 
opposite kinds of social behavior – in the 
winners and losers (as example, see Fig. 4). It 
was natural to presume that psychoemotional 
disorders induced by repeated experience of 
aggression and accompanied by victories 
(positive emotional background) or by repeated 
experience of social defeats (negative emotional 
background) would evoke different changes in 
the brain, triggering different reactions to the 
drugs. Since the many of drugs used act on the 
receptors, it is natural to assume that receptors 
might become more sensitive to neurotrans-
mitters (sensitization) and, thus, more susceptible 
to drugs, or less sensitive (desensitization). It is 
clear that such changes in the receptors arise in 
response to changes in mediator metabolism 
evoked by social confrontations. Therefore, on 
the one hand, psychoemotional states modify the 
effect of drugs. On the other hand, psychoemo-
tional states themselves can exert significant 
influence on the development of a disease. It is 
also evident that different drugs may be needed 
to arrest the same modified behaviors or 
physiological changes in different individuals 
since such individuals may have varying 
susceptibility to those drugs. The proposed 
model allows investigating the responses of 
individuals with opposite psychoemotional states 
to the administration of the same drug. In 
modern pharmacology priority has been attached 
to personal therapy, which is thought to be a key 
to effective treatment. 
 
Conclusion: perspectives of the use of social 
models for pharmacological screening of 
psychotropic drugs 
Over many years the studies have focused on 
search of adequate models of psychoemotional 
disorders, which would allow screening of 
psychotropic drugs [10-24]. The models that are 
gaining in popularity include biosocial models to 
study the consequences of acute or chronic social 
conflicts and social stress in animals [16, 18, 19, 
25-29]. In this connection our experimental 
behavioral approach is up to date and in the 
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mainstream of contemporary studies. It allows 
screening of novel psychotropic drugs in simulated 
clinical conditions and detecting their preventive 
and therapeutic properties and efficacy. In our view, 
this method could help if not to entirely avoid but to 
minimize the phase of clinical trials of novel drugs 
on patients. Study of dynamic changes in brain 
neurotransmitter systems (metabolism, receptors, 
genes expression) – from norm to severe pathology 
may also give valuable results and could help to 
identify adequate methods of pharmacological 
correction depending on the stage of a disease. The 
action of drugs should be investigated with respect 
to the neurochemical background specifically 
altered under the influence of emotional pathogenic 
factors. Studies on animals treated with psycho-
tropic drugs that are commonly used in medical 
practice for treatment of depression, anxiety and 
aggression have shown a close correspondence 
of their effect to that in humans. A large variety 
of behavioral pathologies (anxious depression, 
reduced sociability, pronounced aggression, 
anxiety, anhedonia etc.), which are accompanied 
by somatic changes (gastric mucosa damage, 
reduced gonadal function, psychogenic immune 
deficiency and others) in animals gives grounds 
to suppose that this approach could be 
extensively used in many medical-biological 
investigations for the study of a broad spectrum 
of problems in social biology and biological 
psychiatry.  
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